Clinical trials: Insulinoma
Gastrinoma, Glucagonoma
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
This randomized phase II trial studies how well everolimus works in treating patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Liver Metastases
- Trial name
- NCT02031536
- Testing
- everolimus
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00227617
- Testing
- bevacizumab, 5-fluorouracil, leucovorin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Thyroid Cancer, Medullary, Carcinoid Tumor
18F-FDOPA PET in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic.
- Conditions
- Thyroid Cancer, Medullary, Carcinoid Tumor, Pheochromocytoma, Paraganglioma
- Trial name
- NCT02431715
- Testing
- [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Neuroendocrine Tumors, Carcinoid Tumor
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- NCT04915144
- Testing
- 177Lu-DOTATOC
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Insulinoma
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect insulinoma, like the widely studied [68Ga]Ga-NOTA-exendin-4.
- Trial name
- NCT05034783
- Testing
- [68Ga]Ga-HBED-CC-exendin-4, [68Ga]Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Tumor, Benign, Pancreatic Neoplasms
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst
- Trial name
- LTW (NCT03147768)
- Testing
- Distal Pancreatectomy Sealing Using LTW
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Laser Tissue Welding, Inc.
Gastrinoma, Glucagonoma
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT02259725
- Testing
- regorafenib, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Insulinoma
68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH
In order to improve the sensitivity and specificity of pre-operative imaging localization of foci in adult endogenous hyperinsulinemic hypoglycaemia (AHH) we aim to evaluate a novel promising imaging compound targeting the…
- Trial name
- GLP-1-AHH (NCT03189953)
- Testing
- 68Ga-NODAGA-exendin 4 PET/CT
- Volunteers
- 56 people
- Sponsor
- Radboud University Medical Center
Congenital Hyperinsulinism, Insulinoma
Pasireotide in Hyperinsulinemic Hypoglycemia
This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.
- Conditions
- Congenital Hyperinsulinism, Insulinoma, Hyperinsulinism
- Trial name
- NCT03053284
- Testing
- Pasireotide 0.6Mg Solution for Injection, Saline Solution
- Sponsor
- Montefiore Medical Center
Insulinoma; Pancreas
Blinded Resection in Case of the Pancreatic Insulinoma
The blinded resection avoided in case of pancreatic insulinoma
- Trial name
- NCT04741152
- Testing
- Pancreatic resection
- Volunteers
- 197 people
- Sponsor
- Vishnevsky Center of Surgery
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1
- Trial name
- NCT00454363
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Insulinoma
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
Glucagon-like peptide-1 receptor (GLP-1R) is a kind of G protein coupled receptor which regulate the insulin secretion and serves as potential target in the diagnosis of functional pancreas neuroendocrine tumor.
- Trial name
- NCT04185350
- Testing
- 68Ga-NOTA-MAL-Cys39-exendin-4
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Hyperinsulinemic Hypoglycemia, Insulinoma
Application of Raw Corn Starch on Patients With Insulinoma
This will be a prospective single-arm before-and-after clinical trial in which raw corn starch (RCS) will be first applied on patients with unoperated insulinoma.
- Conditions
- Hyperinsulinemic Hypoglycemia, Insulinoma, Raw Corn Starch
- Trial name
- NCT03930368
- Testing
- low GI diet with regular supplementation of raw corn starch
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth.
- Trial name
- NCT01056601
- Testing
- Bortezomib, Panobinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
- Trial name
- NCT00730483
- Testing
- PVA microporous hydrospheres/doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Gastrinoma, Glucagonoma
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
This phase II trial studies how well dovitinib lactate works in treating patients with pancreatic neuroendocrine tumors. Dovitinib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor
- Trial name
- NCT02108782
- Testing
- dovitinib lactate, pharmacological study, laboratory biomarker analysis
- Sponsor
- Academic and Community Cancer Research United
Hypercalcemia, Familial Primary Hyperparathyroidism
Cinacalcet to Treat Familial Primary Hyperparathyroidism
This study will evaluate the benefits and side effects of a new medication called Cinacalcet for treating patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 (MEN1) or type 2A (MEN2A).
- Trial name
- NCT00325104
- Testing
- Parathyroid hormone testing, Serum calcium testing
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Estrogen Receptor-positive Breast Cancer, Gastrinoma
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
This phase II trial studies how well real-time pharmacokinetic therapeutic drug monitoring works in preventing stomatitis from developing in patients with hormone receptor positive breast cancer, pancreatic neuroendocrine tumors…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma, HER2-negative Breast Cancer
- Trial name
- NCT02273752
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University